Skip to main content

Table 2 Genes differentially expressed between non-responders and responders in pretreatment samples

From: Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609)

Gene symbol

Description

log2 FC (R/NR)

Upregulated genes

 CHGB

Chromogranin B

1.3

 TPTE

Transmembrane phosphatase with tensin homology

1.2

 NMBR

Neuromedin-B-preferring bombesin receptor

1.0

 MYO3B

Myosin IIIB

1.1

 CEP72

Centrosomal protein 72

0.9

 GRB14

Growth factor receptor bound protein 14

1.0

 MEGF10

Multiple epidermal growth factor-like domains protein 10

1.0

 RP5-1043L13,1

LncRNA

1.0

 ZXDC

ZXD family zinc finger C

0.3

 VSX1

Visual system homeobox 1

0.9

 MBTPS1

Membrane bound transcription factor peptidase, site 1

0.6

 CTRL

Chymotrypsin Like

0.4

 SESN3

Sestrin 3

0.9

 PSKH1

Protein serine kinase H1

0.4

 TPPP

Tubulin polymerization promoting protein

1.0

 LINC00578

Long intergenic non-protein coding RNA 578

1.0

 RP11-712B9,2

LncRNA

0.9

 GBA3

Glucosylceramidase beta 3

0.9

 CPLX2

Complexin 2

0.7

 HSDL1

Hydroxysteroid dehydrogenase like 1

0.5

 AC008174,3

LncRNA

0.9

 FUK

Fucokinase

0.5

 MT1L

Metallothionein 1L

0.9

Downregulated genes

 ASAH1

N-Acylsphingosine amidohydrolase 1

− 0.8

 ANK1

Ankyrin 1

− 1.0

 PCSK1

Proprotein convertase subtilisin/kexin type 1

− 0.9

 SEZ6L

Seizure related 6 homolog like

− 0.9

 TMC3

Transmembrane channel like 3

− 0.9

 RP11-761I4,3

LncRNA

− 1.0

 KCNK3

Potassium two pore domain channel subfamily K member 3

− 0.9

  1. Genes were selected by class comparison analysis at a FDR of 0.1; FC fold change, NR non-responder, R responder